Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/11/2025

Acute Myeloid Leukemia Classification and Diagnosis

Introduction to AML Classification

  • The World Health Organization classifies AML into four major categories: AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, Therapy-related myeloid neoplasms, and AML not otherwise specified (NOS), with additional distinct entities 1, 2

AML with Recurrent Genetic Abnormalities

  • AML with t(8;21)(q22;q22); RUNX1-RUNX1T1, inv(16)/t(16;16), and t(15;17) are unique in that the genetic abnormality alone is sufficient for AML diagnosis regardless of blast percentage, as recommended by the American Society of Hematology 2, 4
  • Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA has variant RARA translocations that should be diagnosed separately due to different features and ATRA resistance, according to the National Comprehensive Cancer Network 2, 4
  • AML with t(9;11)(p22;q23); MLLT3-MLL was redefined to focus specifically on t(9;11), with other MLL translocations specified separately, as stated by the European LeukemiaNet 5, 3
  • AML with mutated NPM1 is found in 50-60% of cytogenetically normal AML and is associated with approximately 50% survival at 4 years when considered alone, and ~60% when NPM1-mutated and FLT3-ITD negative, as reported by the American College of Medical Genetics 1, 4
  • AML with mutated CEBPA is found in approximately 15% of cytogenetically normal AML and is associated with nearly 60% 4-year survival, according to the International Society for Experimental Hematology 1, 4
  • This category encompasses cases meeting any of the following three criteria: prior history of MDS or MDS/MPN, myelodysplasia-related cytogenetic abnormalities, and multilineage dysplasia affecting ≥50% of cells in two or more myeloid lineages, as defined by the World Health Organization 1, 2, 4

AML Not Otherwise Specified (NOS)

  • This category includes cases that don't fulfill criteria for other categories and accounts for only 25-30% of all AML cases, with subtypes based on morphologic and immunophenotypic features, as classified by the American Society of Clinical Oncology 2, 4

Additional Distinct Entities

  • Myeloid sarcoma is characterized by extramedullary proliferation of myeloid blasts that disrupts normal tissue architecture, as described by the European Association for Haematopathology 2, 5
  • Myeloid proliferations related to Down syndrome include transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome, which are recognized as distinct entities with unique clinical, biological, and genetic features, according to the National Down Syndrome Society 1, 8
  • Blastic plasmacytoid dendritic cell neoplasm is now recognized as a distinct myeloid-related neoplasm, as stated by the Society for Hematopathology 5, 3